{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:32:18Z","timestamp":1772166738893,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Following external beam radiation therapy (EBRT) with concurrent chemotherapy, we analyzed the benefits of surgical resection for locally advanced cervical carcinoma in terms of the frequency and severity of complications and disease-free survival, including cases of adjuvant hysterectomy after failure of resolution post-brachytherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient and methods<\/jats:title>\n                    <jats:p>Retrospective analysis was utilized to determine the eligibility of 145 cases treated at the National Cancer Institute between January 2015 and June 2021. Of those, 17 patients did not match the requirements, and 8 patients declined to take part in the study. Depending on the major treatment technique, 120 FIGO stage IB3\u2013FIGO stage IVA cervical cancer patients were split into two equal groups of 60 patients each. Sixty patients (50%) received neo-adjuvant EBRT and concurrent platinum-based chemotherapy followed by hysterectomy (group A) and 60 (50%) received definitive radiotherapy only (group B).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The age at diagnosis of patients was similar, with a mean of 52.5 (range 34\u201377) and 53.4 (range 25 81) years in group A and group B, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.675). Majority of the cases in both groups were pathologically squamous cell carcinomas (88.3% in group A and 83.3% in group B) and of grade II differentiation (73.7% in group A and 71.2% in group B). Majority of cases in both groups being FIGO stage II (45% in group A and 40% in group B) and FIGO stage III (40% in group A and 43.3% in group B). Only 17 patients (28.3%) in group A had postoperative complications, while 37 patients (61.7%) in group B suffered from post-treatment complications (\n                      <jats:italic>P<\/jats:italic>\n                      value\u2009&lt;\u20090.001). In group B, 14 patients (23.3%) failed to show complete remission of the disease after completion of treatment, with a mean residual disease of 4.3\u00a0cm in diameter (range 2\u20136\u00a0cm), either local or nodal. Salvage hysterectomy post-definitive radiotherapy was done for 8 patients with residual disease (13.3%). In group A, 48 patients had no recurrence during follow-up (80%), while 11 of the patients had either locoregional or metastatic recurrences, or both (18.3%). DFS was comparable between both groups (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.493), excluding 23.3% of group B where failure of complete remission of the disease after completion of treatment barred the patients from the disease-free calculations. The 1-year DFS was 88.1% in group A and 82.6% in group B, while the 3-year DFS was 74.1% in group A and 70.1% in group B.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There was no difference in disease-free survival or the incidence of locoregional and metastatic recurrence between patients with cervical cancer who had surgery and those who received brachytherapy following EBRT and concomitant chemotherapy. In almost 50% of cases, the surgical patients showed full pathological recovery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43046-025-00292-0","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T07:17:57Z","timestamp":1749280677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant chemoradiation and surgical excision versus definitive radiotherapy for locally advanced cervix uteri carcinoma: in terms of early and late complications and locoregional recurrence"],"prefix":"10.1186","volume":"37","author":[{"given":"Hisham","family":"Khalifa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Ayaty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reham","family":"Oreaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"Emad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Salama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"khaled","family":"Elsebahy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael A. Wahab","family":"Ghoniem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"issue":"1","key":"292_CR1","first-page":"8","volume":"2","author":"A Serarslan","year":"2021","unstructured":"Serarslan A, Meydan D, Yildiz RE. Radical radiotherapy of locally advanced cervix uteri carcinoma. Archives of Cancer Biology and Therapy. 2021;2(1):8\u201314.","journal-title":"Archives of Cancer Biology and Therapy"},{"issue":"2","key":"292_CR2","first-page":"1","volume":"21","author":"W Lu","year":"2021","unstructured":"Lu W, Lu C, Yu Z, Gao L. Chemoradiotherapy alone vs. chemoradiotherapy and hysterectomy for locally advanced cervical cancer: a systematic review and updated meta-analysis. Oncol Lett. 2021;21(2):1\u20131.","journal-title":"Oncol Lett."},{"issue":"1","key":"292_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejso.2019.09.188","volume":"46","author":"W Li","year":"2020","unstructured":"Li W, Liu P, Zhao W, Yin Z, Lin Z, Bin X, Lang J, Chen C. Effects of preoperative radiotherapy or chemoradiotherapy on postoperative pathological outcome of cervical cancer\u2013from the large database of 46,313 cases of cervical cancer in China. Eur J Surg Oncol. 2020;46(1):148\u201354.","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"292_CR4","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1245\/s10434-022-11583-4","volume":"29","author":"A Federico","year":"2022","unstructured":"Federico A, Anchora LP, Gallotta V, Fanfani F, Cosentino F, Turco LC, Bizzarri N, Legge F, Teodorico E, Macchia G, Valentini V. Clinical impact of pathologic residual tumor in locally advanced cervical cancer patients managed by chemoradiotherapy followed by radical surgery: a large, multicenter, retrospective study. Ann Surg Oncol. 2022;29(8):4806\u201314.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"292_CR5","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1016\/j.ygyno.2007.07.006","volume":"107","author":"G Ferrandina","year":"2007","unstructured":"Ferrandina G, Legge F, Fagotti A, Fanfani F, Distefano M, Morganti A, Cellini N, Scambia G. Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures. Gynecol Oncol. 2007;107(1):S127\u201332.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"292_CR6","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1006\/gyno.2000.5862","volume":"78","author":"S Mancuso","year":"2000","unstructured":"Mancuso S, Smaniotto D, Panici PB, Favale B, Greggi S, Manfredi R, Margariti PA, Morganti AG, Scambia G, Tortoreto F, Valentini V. Phase I-II trial of preoperative chemoradiation in locally advanced cervical carcinoma. Gynaecol Oncol. 2000;78(3):324\u20138.","journal-title":"Gynaecol Oncol"},{"issue":"3","key":"292_CR7","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.1016\/j.ygyno.2005.07.074","volume":"99","author":"D Mariagrazia","year":"2005","unstructured":"Mariagrazia D, Anna F, Gabriella F, Francesco F, Daniela S, Alessio M, Giovanni S. Preoperative chemoradiotherapy in locally advanced cervical cancer: long-term outcome and complications. Gynaecol Oncol. 2005;99(3):S166\u201370.","journal-title":"Gynaecol Oncol"},{"issue":"6","key":"292_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/IGC.0b013e3181a8b08f","volume":"19","author":"F Fanfani","year":"2009","unstructured":"Fanfani F, Fagotti A, Ferrandina G, Raspagliesi F, Ditto A, Cerrotta AM, Morganti A, Smaniotto D, Scambia G. Neoadjuvant chemoradiation followed by radical hysterectomy in FIGO Stage IIIB cervical cancer: feasibility, complications, and clinical outcome. Int J Gynecol Cancer. 2009;19(6):1119\u201324.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"292_CR9","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.3802\/jgo.2017.28.e34","volume":"28","author":"F Landoni","year":"2017","unstructured":"Landoni F, Colombo A, Milani R, Placa F, Zanagnolo V, Mangioni C. Randomized study between radical surgery and radiotherapy for the treatment of stage IB\u2013IIA cervical cancer: 20-year update. J Gynaecol Oncol. 2017;28(3):e34.","journal-title":"J Gynaecol Oncol"},{"issue":"1","key":"292_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7819-7-19","volume":"7","author":"L Cetina","year":"2009","unstructured":"Cetina L, Garcia-Arias A, Candelaria M, Cant\u00fa D, Rivera L, Coronel J, Bazan-Perkins B, Flores V, Gonzalez A, Due\u00f1as-Gonz\u00e1lez A. Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIB cervical cancer patients. World J Surg Oncol. 2009;7(1):1\u20138.","journal-title":"World J Surg Oncol"},{"issue":"8","key":"292_CR11","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1093\/annonc\/mdt142","volume":"24","author":"L Cetina","year":"2013","unstructured":"Cetina L, Gonz\u00e1lez-Enciso A, Cant\u00fa D, Coronel J, P\u00e9rez-Montiel D, Hinojosa J, Serrano A, Rivera L, Poitevin A, Mota A, Trejo E. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2\u2013IIB cervical cancer patients. Ann Oncol. 2013;24(8):2043\u20137.","journal-title":"Ann Oncol"},{"issue":"10","key":"292_CR12","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.ejso.2016.05.011","volume":"42","author":"F Fanfani","year":"2016","unstructured":"Fanfani F, Vizza E, Landoni F, De Iaco P, Ferrandina G, Corrado G, Gallotta V, Gambacorta MA, Fagotti A, Monterossi G, Perrone AM. Radical hysterectomy after chemoradiation in FIGO stage III cervical cancer patients versus chemoradiation and brachytherapy: Complications and 3-years survival. Eur J Surg Oncol. 2016;42(10):1519\u201325.","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"292_CR13","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s00066-017-1174-1","volume":"193","author":"P Hass","year":"2017","unstructured":"Hass P, Eggemann H, Costa SD, Ignatov A. Adjuvant hysterectomy after radiochemotherapy for locally advanced cervical cancer. Strahlenther Onkol. 2017;193(12):1048\u201355.","journal-title":"Strahlenther Onkol"},{"issue":"24","key":"292_CR14","doi-asserted-by":"publisher","first-page":"6190","DOI":"10.3390\/cancers13246190","volume":"13","author":"KV Kol","year":"2021","unstructured":"Kol KV, Ebisch R, Piek J, Beugeling M, Vergeldt T, Bekkers R. Adjuvant Hysterectomy for Cervical Cancer patienys treated with chemoradiation therapy. A systematic review on the pathology-proven residual disease rate. Cancers (basel). 2021;13(24):6190.","journal-title":"Cancers (basel)."},{"key":"292_CR15","doi-asserted-by":"crossref","unstructured":"Wang N, Li WW, Li JP, Liu JY, Zhou YC, Zhang Y, Hu J, Huang YH, Chen Y, Wei LC, Shi M. Comparison of concurrent chemoradiotherapy followed by radical surgery and high-dose-rate intracavitary brachytherapy: a retrospective study of 240 patients with FIGO stage IIB cervical carcinoma. OncoTargets Ther. 2014:91\u2013100.","DOI":"10.2147\/OTT.S52710"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00292-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00292-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00292-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T07:18:00Z","timestamp":1749280680000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-025-00292-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["292"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00292-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5187632\/v1","asserted-by":"object"}]},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Cairo University\u2019s National Cancer Institute Ethics Committee. At the time of their admission, every participant consented in writing to the use of their data for medical study. The study was conducted in accordance with the Helsinki Declaration. The patient gave written, informed consent for the original article to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}